Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company …

… Q3 Successfully closed acquisition of eye care supplier Pillar5 Pharma … comparable period. In the third quarter fiscal 2026, the … or more       Third Quarter Fiscal 2026 Conference Call, Accompanying … cash paid for capital expenditures. Net Debt: Calculated …

… production in existing facilities across pharmaceuticals, chemicals, steel, and … with third quarter CapEx revenues up 37% versus the third quarter of … at quarter end. Capital expenditures were $4.9 million … say that typically, our Q3 is always the highest …

… Q3 remained healthy at 1.06:1. Revenues for the third quarter … . Moving to earnings. Third quarter adjusted earnings from operations … things like mail order pharmacy. So we believe that … kind of influenced capital expenditure plans more recently? Douglas …

Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.96; adjusted EPS increased to $2.53 Fiscal 2026 outlook maintained DUBLIN, IRELAND, Feb. 04, 2026 ( …

… fiscal year. Effective capital expenditure, which includes grants for … to biologics‑focused incentives.  Sun Pharma — Large‑cap proxy for … biologics/complex pharma as domestic capability scales. … s Buy Upgrade On Strong Q3 Beat — Check Hiked Target …

… efficiency across its pharmaceutical distribution and specialty … . “McKesson reported strong third quarter operational results with broad … grew sales in Q3 Tyler also emphasized the … providers and pharmacies. McKesson acquisition and expenditures A key …

… the latest Q3 results 2026 updates of Sun Pharmaceutical Industries, GAIL … the third quarter compared to Rs 43.29 crore in Q3 FY25 … , the statement said. Total expenditure for the … 490.6 crore for the third quarter ended December 2025, mainly …

The Mikaela Naylon Give Kids a Chance Act reauthorizes the Pediatric Priority Review Voucher (PPRV) Program and extends eligibility for medicines achieving U.S. FDA approval before September 2029 The Pediatric Priority Review Voucher program encourages the …

… by operating activities, less capital expenditures and with that I’m … categories that we track, financial, pharma, retail, packaged goods, et cetera … the momentum continues into the third quarter. But I should just say …